Full-Time

Head of Clinical Research

Metabolic Diseases

Confirmed live in the last 24 hours

Tessera Therapeutics

Tessera Therapeutics

201-500 employees

Develops gene editing technology for genetic medicine

Biotechnology
Healthcare

Senior, Expert

Cambridge, MA, USA

Category
Genomics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • MD/PhD or equivalent degree with relevant internal medicine training and board certification
  • 15 years of industry experience in clinical development within a pharmaceutical or biotechnology company
  • Designing, implementing, and overseeing multiple early-stage clinical studies
  • Authoring documents required for clinical studies, including study protocols, investigator brochures, regulatory briefing packages and dossiers to support IND/CTA/CTN
  • Direct experience with IND/CTA submissions
  • Thorough understanding of ICH and GCP guidelines
  • Understanding of clinical research methodology and biostatistics principles
  • Demonstrated track record of overseeing a clinical team and successfully completing clinical studies
  • Effective communication and presentation skills
Responsibilities
  • Providing clinical leadership and medical representation for the liver Gene WritingTM programs
  • Ensuring a streamlined and innovative clinical development and medical strategy
  • Authoring medical components for clinical development plans, study protocols, investigator brochures, informed consents, SAPs, pharmacy manuals and associated clinical/regulatory documents
  • Hiring, developing and managing clinical development resources in accordance with program budget and timelines
  • Overseeing risk-based safety monitoring of clinical studies
  • Interpretation and analysis of clinical study safety and efficacy data
  • Preparation of meeting abstracts, posters, presentations, and publications for internal management review and external scientific/clinical meetings
  • Maintaining a constant focus on patient wellbeing across the organization

Tessera Therapeutics focuses on genetic medicine, specifically through a technology called Gene Writing, which enables precise modifications to the human genome. This technology allows for permanent changes to genetic material in any cell, aiming to cure diseases at their source. Tessera's Gene Writing can perform both small and large genetic alterations, making it applicable to a wide range of genetic disorders. The company collaborates with research institutions, pharmaceutical companies, and healthcare providers to develop new treatments. Tessera generates revenue through partnerships, licensing agreements, and the potential sale of its technology. With significant funding secured, Tessera aims to advance its platform and fulfill its goal of curing diseases by rewriting genetic code.

Company Stage

Series C

Total Funding

$517.2M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

-14%

1 year growth

-13%

2 year growth

13%
Simplify Jobs

Simplify's Take

What believers are saying

  • Tessera's innovative Gene Writing technology has the potential to cure previously untreatable genetic conditions, offering a transformative impact on healthcare.
  • The company's strategic partnerships and licensing agreements with major pharmaceutical firms and research institutions can drive significant revenue growth and market penetration.
  • Recent leadership appointments, including a new General Counsel and Chief Regulatory Officer, bring extensive industry experience that can guide the company through regulatory and commercial milestones.

What critics are saying

  • The highly competitive biotechnology sector requires continuous innovation to maintain Tessera's market position.
  • Regulatory hurdles and the complexity of clinical trials for genetic therapies could delay product development and commercialization.

What makes Tessera Therapeutics unique

  • Tessera Therapeutics' Gene Writing technology offers a unique capability to make precise and permanent genetic alterations, setting it apart from traditional gene editing methods.
  • The company's focus on a wide range of genetic disorders, from phenylketonuria to sickle cell disease, showcases the versatility and broad applicability of its platform.
  • Securing $300 million in Series C financing highlights strong investor confidence and provides substantial resources for advancing their groundbreaking technology.

Help us improve and share your feedback! Did you find this helpful?